SAOS-2人成骨肉瘤细胞

Saos-2/Saos-2细胞系/Saos-2细胞株/Saos-2人骨肉瘤细胞

Cell line name SaOS-2

Synonyms SAOS-2; Saos-2; SAOS 2; Saos 2; Saos2; SaOs2; SAOS2; Sarcoma OSteogenic-2; SaOS; SAOS

Accession CVCL_0548

Resource Identification Initiative To cite this cell line use: SaOS-2 (RRID:CVCL_0548)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 771.

Population: Caucasian.

Doubling time: 48 hours (PubMed=16888811); 45.7 +- 3.3 hours (PubMed=10763916); ~48 hours (PubMed=21519327); 35-40 hours (CLS=300331); ~43 hours (DSMZ=ACC-243).

Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Bone; UBERON=UBERON_0002481.

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4

Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Cancer Genet. Cytogenet. 140:145-152(2003)

 

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809

Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Cancer Res. 64:3395-3405(2004)

 

PubMed=15736406

Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.

Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.

Anticancer Res. 24:3743-3748(2004)

 

PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097

Hausser H.-J., Brenner R.E.

Phenotypic instability of Saos-2 cells in long-term culture.

Biochem. Biophys. Res. Commun. 333:216-222(2005)

 

PubMed=16888811; DOI=10.1002/jcb.21073

Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.

Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.

J. Cell. Biochem. 100:339-348(2007)

 

PubMed=17354236; DOI=10.1002/ijc.22643

Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

Int. J. Cancer 121:199-205(2007)

 

PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729

Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.

Levels of p27(kip1) determine Aplidin sensitivity.

Mol. Cancer Ther. 6:1310-1316(2007)

 

PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003

Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.

Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.

Cancer Genet. Cytogenet. 179:52-61(2007)